Sensex falls over 1,400 points in 4 days; why is the Indian stock market on a downtrend? EXPLAINED - Mint

FDA approves Alhemo® as once-daily prophylactic treatment to prevent or reduce the frequency of bleeding episodes for adults and children 12 years of age and older with hemophilia A or B (HA/HB) without inhibitors – PR Newswire

1 August 2025

FDA approves Alhemo® as once-daily prophylactic treatment to prevent or reduce the frequency of bleeding episodes for adults and children 12 years of age and older with hemophilia A or B (HA/HB) without inhibitors PR Newswire
European regulatory authority adopts positive opinion for Novo Nordisk’s Alhemo® (concizumab), recommending label expansion to treat haemophilia A and B without inhibitors Yahoo Finance
FDA approves concizumab-mtci for hemophilia A/B without inhibitors in patients 12 years and older Contemporary Pediatrics
Novo Nordisk’s Alhemo Recommended for Expanded Use in Europe for Haemophilia A and B Insider Monkey
European Medicines Agency Issues Positive Opinion for Concizumab Label Update in Hemophilia Docwire News